These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16888783)

  • 1. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
    Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
    [No Abstract]   [Full Text] [Related]  

  • 2. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
    Bernardeschi P; Pirrotta MT; Montenora I; Giustarini G; Ferreri MI; Simi P; Fiorentini G
    Leuk Res; 2010 Apr; 34(4):e104-5. PubMed ID: 19889456
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M
    Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516
    [No Abstract]   [Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    Libby E; Candelaria-Quintana D; Moualla H; Abdul-Jaleel M; Rabinowitz I
    Am J Hematol; 2010 Sep; 85(9):733-4. PubMed ID: 20669178
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
    Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
    Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
    Mele G; Pinna S; Melpignano A; Quarta G
    Clin Ther; 2010 May; 32(5):915-9. PubMed ID: 20685499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
    Ali R; Beksac M; Ozkalemkas F; Ozkocaman V; Ozkan A; Ozcelik T; Tunali A
    Leuk Lymphoma; 2007 Jul; 48(7):1426-8. PubMed ID: 17613776
    [No Abstract]   [Full Text] [Related]  

  • 13. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
    Tong Y; Qian J; Li Y; Meng H; Jin J
    Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2015 Jan; 56(1):232-5. PubMed ID: 24884320
    [No Abstract]   [Full Text] [Related]  

  • 17. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
    Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
    Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
    Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful bortezomib-based treatment in POEMS syndrome.
    Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
    Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.